VERA
Vera Therapeutics Inc
30.40$
-1.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Vera Therapeutics Inc (VERA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -100 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.3 | -2.7 | -2.4 | -27 | -4.1 | -7.7 | -5.5 | -6.4 | -9.0 | -19 | -18 | -21 | -26 | -18 | -23 | -25 | -34 | -25 | -37 | -39 | -54 | -55 | -62 | -70 | -107 | -100 | -339 | |
| 0.1 | 0.1 | 0.7 | -0.6 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | -0.1 | -0.2 | -0.6 | -0.5 | 0.5 | 0.0 | -1.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.1 | 0.7 | |
| 0.1 | 0.0 | 0.1 | 0.1 | 0.4 | 0.7 | 0.9 | 1.0 | 1.7 | 2.0 | 2.5 | 2.7 | 2.7 | 2.7 | 2.9 | 3.2 | 4.1 | 4.9 | 5.6 | 6.2 | 7.7 | 9.5 | 9.7 | 11 | 13 | 16 | 50 | |
| 0.0 | 0.4 | 1.7 | 16 | -0.2 | -0.2 | 0.8 | 0.8 | 1.7 | 2.0 | 2.5 | 2.7 | 2.7 | 3.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.4 | 0.0 | 0.1 | 0.7 | -2.4 | 0.9 | 4.3 | 5.9 | -7.2 | -0.5 | 8.5 | 1.0 | 0.1 | -4.9 | -2.1 | -8.6 | 6.1 | 5.9 | -0.7 | -9.4 | 13 | 8.7 | 10 | -14 | -6.4 | -1.1 | |
| 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.2 | 0.6 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.6 | |
| -0.1 | 0.0 | 0.8 | 0.1 | 0.8 | 0.8 | -5.0 | -5.0 | -39 | -42 | -2.4 | 13 | 12 | -86 | 16 | 19 | -219 | -23 | 38 | -221 | 15 | 29 | 70 | 81 | -138 | 33 | 45 | |
| – | – | -0.1 | – | 0.0 | 0.0 | – | – | 86 | -6.0 | -79 | 0.8 | 0.2 | – | – | – | – | – | 0.0 | 0.0 | – | – | – | 0.0 | – | – | – | |
| 5.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 4.9 | 4.9 | -6.2 | -6.2 | -6.2 | 20 | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | |
| 5.0 | 0.6 | -0.1 | 80 | 0.0 | 49 | 49 | 4.9 | 80 | 0.0 | 0.9 | 21 | 108 | 0.4 | 0.3 | 25 | 277 | 3.4 | 0.7 | 326 | 1.5 | 20 | 0.8 | 286 | 3.9 | 1.9 | 293 | |
| 2.6 | -2.1 | -2.5 | 52 | -4.1 | 42 | -5.5 | -6.5 | 32 | -61 | -20 | 13 | 94 | -104 | -6.4 | 18 | 23 | -44 | 2.2 | 65 | -38 | -6.0 | 8.7 | 297 | -240 | -65 | -0.2 | |
| -2.4 | -2.7 | -2.4 | -27 | -4.1 | -7.7 | -5.5 | -6.4 | -9.0 | -19 | -18 | -21 | -26 | -18 | -23 | -25 | -34 | -25 | -37 | -40 | -55 | -55 | -62 | -70 | -107 | -100 | -339 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.